Dual-Target Bispecific Nanobody Therapy for Sickle Cell Disease: Innovatively Engaging ALB and CFP

VHH-P789 is a humanized bispecific and bivalent nanobody-based immunoglobulin single chain designed to target albumin (ALB) and complement factor properdin (CFP). Manufactured using Chinese hamster ovary (CHO) cells, VHH-P789 is currently in the Biological Testing stage. This innovative molecule is engineered for the potential treatment of sickle cell disease, aiming to address disease-modifying mechanisms via dual modulation of ALB and CFP. By simultaneously engaging two clinically relevant targets, VHH-P789 offers a versatile therapeutic approach for this severe hematological disorder.

Licensing Opportunity

VHH-P789 is available for licensing and collaborative development. We welcome inquiries from partners and institutions interested in advancing this promising bispecific nanobody for sickle cell disease treatment.

Development Phase

Modality

VHH-P789 leverages the structural advantages of nanobodies as a bispecific, bivalent single chain immunoglobulin. Its humanized composition and small molecular size enable improved tissue penetration and pharmacokinetic stability, which are critical for targeting pathophysiological processes in sickle cell disease. The nanobody format provides inherent thermal and chemical stability, and the bispecificity enhances functional reach by simultaneously targeting distinct molecules. Expression in CHO cells ensures scalability and manufacturability aligned with industry standards, making VHH-P789 an attractive candidate for advanced therapeutic development.

Target

ALB and CFP are pivotal molecular targets with essential roles in systemic physiology. ALB, the most abundant plasma protein, is involved in transport and homeostatic regulation, predominantly expressed in hepatocytes. CFP, a positive regulator of the alternative complement pathway, is mainly produced by immune cells and contributes to host defense and inflammation. Both ALB and CFP are implicated in the pathogenesis of sickle cell disease through protein transport dynamics and complement activation, respectively. Targeting both ALB and CFP with VHH-P789 maximizes strategic therapeutic impact, offering a novel route to modulate key pathological pathways and advance beyond traditional sickle cell disease treatments.

Mechanism of Action

VHH-P789 acts through the combined inhibition and modulation of ALB and CFP. By targeting ALB, it may influence systemic transport and distribution of critical mediators, while engagement with CFP modulates the complement pathway, potentially ameliorating inflammatory cascades associated with sickle cell disease. The nanobody design allows for high affinitive and selective interaction with both targets, enabling synchronized biological interventions. VHH-P789’s modular nanobody platform supports further extension to advanced modalities, including conjugation or applications as a basis for multi-specific or antibody drug conjugate therapeutics.

Sickle Cell Disease

Sickle cell disease is a severe hereditary hemoglobinopathy affecting millions globally, with the highest prevalence in individuals of African, Middle Eastern, and Indian descent. The disease is characterized by the production of abnormal hemoglobin S, leading to chronic hemolytic anemia, vaso-occlusive crises, and multi-organ complications. Current mainstay treatments encompass supportive care, blood transfusions, hydroxyurea therapy, and allogeneic stem cell transplantation. However, these approaches are limited by accessibility, adverse effects, and incomplete efficacy. Many patients continue to experience significant morbidity and have unmet needs for disease-modifying therapies. Targeting the multifactorial pathogenesis of sickle cell disease via dual engagement of ALB and CFP, VHH-P789 introduces a potentially transformative approach aimed at addressing underlying inflammation and transport dysfunction, offering promise for improved outcomes in this challenging disorder.